Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 8, 2026 · Financial results · Financial statements
Seaport Therapeutics, Inc.
6
Financial results
Jun 8, 2026
| Item 2.02 | Released results of operations or financial condition |
| Item 9.01 | Financial statements and exhibits |
Seaport Therapeutics, Inc. filed this to release quarterly or annual financial results outside the normal reporting cycle.
1 Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress New data from Phase 1 trial of GlyphAgo TM build upon previously reported topline data and further demonstrate GlyphAgo TM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing Enrollment in Phase 2b BUOY-1 trial of GlyphAllo TM is on track with topline data expected in 1H 2027; Seaport dos…
The filing reports Items 2.02, 9.01. None of these codes are typically workforce-tagged, but analysts still review them for indirect labor-market signals.
Seaport Therapeutics, Inc. filed this 8-K with the SEC. cutoffs links it to the employer's layoff history, visa filings, and other labor-market signals.
